ImmunityBio slides as FDA warning letter over ANKTIVA promotions keeps pressure on shares
ImmunityBio (IBRX) shares are sliding as investors continue to digest an FDA warning letter made public on March 24, 2026, targeting promotional claims for its bladder-cancer drug ANKTIVA. The FDA said a TV ad and a podcast created a misleading impression, including referring to the therapy as a "cancer vaccine," increasing regulatory overhang near $7.09.
1) What’s moving the stock
ImmunityBio shares are down in Monday trading as the market continues to reprice regulatory and execution risk following a recent FDA enforcement action tied to ANKTIVA promotions. The overhang stems from a March 13 FDA warning letter that was posted publicly on March 24, 2026, flagging statements in a TV advertisement and a podcast appearance that the agency said were false or misleading, including characterizing the product as a “cancer vaccine.” (fiercepharma.com)
2) Why it matters
For commercial-stage biotechs, promotional compliance is tightly linked to growth expectations: FDA enforcement can force companies to pull or revise materials, issue corrective communications, and divert management focus at a time when investors want clean execution on sales ramp and pipeline expansion. The FDA letter also escalated attention because it referenced prior agency communications, raising concern that future promotion will be scrutinized more intensely. (fiercepharma.com)
3) What investors are watching next
Key near-term catalysts include the company’s response timeline to the FDA letter and any additional updates on regulatory plans for expanded use of ANKTIVA, including recently discussed submission/resubmission activity in bladder cancer. Traders are also watching whether volatility persists as the stock searches for a post-letter floor after last week’s sharp selloff. (ng.investing.com)